AMH, FSH and Ovarian Reserve: Why Female Fertility Markers Are Reviewed Before a Peptide Protocol
Anti-Müllerian hormone (AMH) and follicle-stimulating hormone (FSH) offer different views of ovarian function, and neither is a verdict on fertility. Here is how they are read, and why they matter when a woman is considering a peptide protocol.
By UAE Peptide Clinic Research Desk
Many women who ask about peptide therapy are also thinking, sometimes quietly, about fertility: whether they may want a pregnancy in the next few years, whether their cycles are changing, or whether a protocol could interfere with either. Blood markers of ovarian function help frame those conversations. They are also frequently misunderstood, which is why a clinician needs to interpret them alongside age, cycle history and symptoms.
What AMH actually measures
Anti-Müllerian hormone is produced by the small, growing follicles within the ovary. Because the number of these follicles broadly reflects the pool of remaining eggs, AMH is often described as a marker of ovarian reserve. Levels tend to decline gradually through the thirties and fall towards undetectable around the menopause transition.
The key word is quantity. Research suggests AMH tells us something about how many follicles are available to respond to stimulation, but much less about egg quality, which is driven chiefly by age. A woman in her late twenties with a low AMH and a woman in her early forties with the same value are not in the same position, and the number alone cannot predict the chance of conceiving naturally.
AMH describes how many follicles are in the pool, not how likely any one cycle is to succeed.
Where FSH and oestradiol fit
Follicle-stimulating hormone is released by the pituitary to recruit follicles. When ovarian reserve falls, the ovaries signal less strongly back to the brain, and the pituitary compensates by raising FSH. A persistently raised FSH on an early-cycle blood test can therefore suggest diminished reserve.
Unlike AMH, FSH fluctuates from cycle to cycle and must be timed correctly, usually on days two to five of a natural cycle and always paired with oestradiol. A raised oestradiol can suppress FSH and make a single result look reassuring when it is not. For this reason, one isolated value is rarely enough, and repeat testing is common.
- AMH: can be drawn on any day of the cycle and reflects the follicle pool.
- FSH with oestradiol: timed to the early follicular phase; more variable between cycles.
- Antral follicle count on ultrasound: a complementary, direct view of the ovaries.
- LH, prolactin and thyroid markers: help separate ovarian causes from pituitary or thyroid ones.
Why this matters before a peptide protocol
Several peptides discussed in clinical settings act on the growth hormone axis, the melanocortin system or tissue-repair pathways. Human data on their use in women who are pregnant, breastfeeding or actively trying to conceive are limited, and for that reason protocols are generally paused during preconception planning, pregnancy and breastfeeding. Knowing where a woman sits on the fertility timeline allows the physician to plan accordingly rather than discover the question midway through a cycle of treatment.
Reproductive markers also help separate symptoms that look alike. Irregular cycles, fatigue and poor sleep can reflect perimenopause, polycystic ovary syndrome, thyroid disease, high prolactin or chronic stress. Each points towards a different clinical path, and the hormone panel is often what distinguishes them.
Clinical nuance: hormonal contraception and recent changes
Hormonal contraception can lower AMH modestly and alter FSH and oestradiol patterns, and these effects typically reverse after stopping. Testing is therefore interpreted in the context of what a woman is taking and when she last changed it. Recent pregnancy, breastfeeding, significant weight change and ovarian surgery can also shift results.
Reading the results sensibly
A low AMH is not a diagnosis of infertility, and a normal AMH is not a guarantee of it. These markers are best viewed as a snapshot that informs timing and planning, ideally discussed with a physician and, where fertility is the priority, a reproductive specialist. Anxiety about a single number is common, and a measured conversation about what it can and cannot say is part of good care.
If you're exploring female hormone markers as part of your protocol, our clinical team can review your case — take the 2-minute quiz at /find-my-stack or book a free consultation at /book.
